stockrow
Friday 6 November 2026
Export XERS’s income statement to Excel — free account
Xeris Biopharma Holdings, Inc.
XERS Healthcare Drug Manufacturers Specialty & Generic
Xeris Biopharma Holdings, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $291.8 million, up 43.7% from fiscal 2024.
- Revenue
- +44.2%
- EPS
- +1,479.0%
- Free cash flow
- +93.2%
- Total debt
- −13.6%
Quarter to September 2026, against a year earlier
15.16
2.08
+15.90%
Follow XERS
Alert me
| Older periods | Dec '25 | Mar '26 | Jun '26 | Sep '26 From the 10-Q filed 5 Nov | |
|---|---|---|---|---|---|
Piotroski F-Score |
+8 more TTM periods Free account |
8 | 8 | 6 | 7 |
| (6.96%) | (108.59%) | 118.22% | (27.11%) | ||
| 0.16% | 3.39% | (4.60%) | (1.64%) | ||
ROIC |
12.65% | 18.32% | 18.88% | 27.22% | |
Return on Tangible Assets |
0.41% | 8.69% | (19.07%) | (4.08%) | |
Average Days of Receivables |
63.85 | 65.26 | 63.23 | 67.99 | |
Free Cash Flow per Share |
0.17 | 0.28 | 0.32 | 0.41 | |
Free Cash Flow |
27.93 | 47.52 | 55.67 | 73.65 | |
Capital Expenditures |
(0.70) | (1.01) | (0.94) | — | |
| Other line items | |||||
Cash ROIC |
8.09% | 13.73% | 15.27% | 19.93% | |
Accounts Receivable Turnover |
6.38 | 6.14 | 6.04 | 6.02 | |
Accounts Payable Turnover |
15.87 | 4.99 | 4.79 | 6.38 | |
Inventory Turnover |
0.73 | 0.70 | 0.61 | 0.64 | |
Average Days of Payables |
26.37 | 94.24 | 75.68 | 63.16 | |
Days of Inventory on Hand |
588.82 | 610.05 | 656.01 | 604.31 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
10.68% | 10.23% | 10.38% | 10.42% | |
Selling, General and Administrative Expense of Revenue |
62.49% | 60.82% | 62.05% | 61.31% | |
Share Based Compensation of Revenue |
7.66% | 7.01% | 8.38% | 8.49% | |
Interest Coverage |
0.86 | 1.25 | 1.30 | 1.70 | |
Operating CF/Net income |
51.67 | 4.04 | (3.30) | (11.34) | |
Depreciation/Fixed assets |
3.25 | 3.21 | 3.37 | 0.00 | |
Capex/Depreciation |
(0.04) | (0.06) | (0.06) | — | |
Revenue per Share |
1.82 | 1.85 | 1.94 | 2.04 | |
Operating CF per Share |
0.18 | 0.28 | 0.33 | 0.41 | |
Capex per Share |
0.00 | (0.01) | (0.01) | 0.00 | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 |
Columns are period end dates · fundamentals updated 5 Nov 2026